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ABSTRACT
Objective Hormone replacement therapy (HRT) is acknowledged as the gold standard for the alleviation of
climacteric vasomotor symptoms. Prothrombotic genetic variants have been suggested to increase thrombotic
risk among HRT users. The aim of the study was to determine whether a positive family history may identify a
genetic predisposition for thrombosis in women before prescribing HRT.
Methods From January 2005 to May 2009, we consecutively enrolled 145 asymptomatic women (mean age
51.2+ 5.4 years) without previous episodes of venous and/or arterial thrombosis referred to our Genetics
Research Unit before starting HRT. A detailed family history was reconstructed and we identified 48 women
(33.1%) with a positive family history, defined as venous thromboembolism and/or stroke or heart attack, in
first-degree relatives before 60 years for men and 65 years for women. A group of 121 women (mean age
54.0+ 9.1 years) with an episode of venous and/or arterial thrombosis was also included. Genetic screening
for factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase C677T polymorphisms
was performed.
Results The frequency of factor V Leiden or prothrombin G20210A mutations was significantly higher both
in asymptomatic women with a positive family history (16.7% vs. 2.1%, p¼ 0.001) and in patients with
thrombosis (12.4% vs. 2.1%; p¼ 0.005) compared with asymptomatic women without a family history.
Multivariate regression analysis showed a synergic effect between the presence of one prothrombotic mutation
and family history on the risk of thrombosis (odds ratio 3.7, 95% confidence interval 1.9–7.2).
Conclusions A positive family history of thrombosis is a sensitive indicator for selected genetic testing in
high-risk women before starting HRT.
INTRODUCTION
Cardiovascular disease is the leading cause of morbidity and
mortality for both men and women. It is well-known that the
risk of cardiovascular disease in women rises sharply after
menopause1,2. This increased risk is mainly attributed to the
reduction in levels of the female sex hormone estrogens,
suggesting that they have cardioprotective effects3–5. Never-
theless, the initial findings of the randomized studies (Heart
and Estrogen/progestin Replacement Study (HERS) and
Women’s Health Initiative (WHI)) generated concern about
the detrimental effect of hormone replacement therapy (HRT)
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on cardiovascular risk6,7. However, re-analysis of the WHI
data has shown that there is a likely beneficial effect on the
cardiovascular system for women who begin treatment with
HRT at or near the time of the menopause8,9. In fact,
according to the recent consensus statement of European
cardiologists and gynecologists, hormone therapy is inap-
propriate for older postmenopausal women no longer
displaying menopausal symptoms10. Congruent trends sug-
gested additional benefit, including reduction of overall
mortality and coronary artery disease, in women starting
HRT between the ages of 50 and 59 years or less than 10 years
after the onset of menopause11. Anyway, assessments of
benefit and risk in younger perimenopausal women is difficult
because it is based on lower levels of evidence10,11.
Recently, it has also been suggested that the risk/benefit
ratio may depend on the genetic predisposition of women, in
particular the presence of inherited thrombotic risk factors
such as factor V Leiden and G20210A prothrombin (PT
G20210A) gene mutation12. In fact, several studies reported a
13–16-fold increased risk of venous thromboembolism during
HRT among women with factor V Leiden13–16. Furthermore,
women on HRT with factor V Leiden or PT G20210A
mutation have a remarkably increased risk of myocardial
infarction or stroke17–19. In addition, a common C677T
polymorphism in the MTHFR gene has been reported to be a
risk factor for deep venous thrombosis14,20. Interestingly,
women with MTHFR 677T variants do not show a decrease
in homocysteine plasma levels in response to HRT when
compared to women with the 677CC genotype, suggesting a
pharmacogenetic variability on the cardiovascular effects21.
At the moment, there is no clinical indication to screen women
for genetic risk factors before prescribing hormone therapy.
The predictive value of a positive family history of early
thrombotic events may be useful in identifying high-risk
women, but the effectiveness of this approach has not yet been
proved.
The objective of this study was to evaluate the sensitivity of
a positive family history of thrombosis in order to identify the
presence of prothrombotic mutations in asymptomatic women
before prescribing HRT.
METHODS
Study population
From January 2005 to May 2009, we consecutively selected
145 asymptomatic women (mean age 51.2+5.4 years)
without previous episodes of venous and/or arterial throm-
bosis who were consecutively referred to our Genetics
Research Unit by gynecologists before starting HRT. In
addition, we included a group of 121 women (mean age
54.0+9.1 years) who were admitted to our Clinical Depart-
ments with an episode of venous and/or arterial thrombosis.
Deep vein thrombosis was objectively diagnosed on the basis
of the results of at least one of these tests: venography,
compression ultrasonography, color Doppler, or plethysmo-
graphy. A diagnosis of pulmonary embolism was made on the
basis of the results of ventilation-perfusion lung scan,
pulmonary angiography, computerized tomography scan or
magnetic resonance imaging. Myocardial infarction was
diagnosed by qualified cardiologists on the basis of typical
electrocardiography changes, elevated cardiac markers and
clinical history. Ischemic stroke was documented clinically by
a neurologist and radiographically by either cranial computed
tomography or magnetic resonance imaging. Venous throm-
boembolism and arterial thrombosis were diagnosed in 20
women (16 suffered from deep vein thrombosis and four from
pulmonary embolism) and 101 women (85 with acute
myocardial syndrome and 16 with ischemic stroke), respec-
tively. No patients had been taking oral contraceptives or
HRT at the time of event. At the moment of blood sampling, a
detailed family history was reconstructed for each woman. A
positive family history was defined as venous thromboembo-
lism and/or stroke or heart attack in first-degree relatives
before 60 years for men and 65 years for women. Women
were also asked about additional acquired thrombotic risk
factors such as hypertension, dyslipidemia, diabetes mellitus
and cigarette smoking. The following definitions were utilized:
hypertension, blood pressure 140/90 mmHg (confirmed by
measurements on several occasions) or antihypertensive
therapy; dyslipidemia, low density lipoprotein cholesterol
130 mg/dl, high density lipoprotein cholesterol 535 mg/dl,
triglycerides 200 mg/dl or use of lipid-lowering medications.
The diagnosis of diabetes mellitus was established according
to World Health Organization criteria: fasting plasma glucose
7.0 mmol/l or antidiabetic medication. Smokers were
classified as individuals who smoked at least three cigarettes
per day at the time of analysis, past smokers had quit smoking
for at least 6 months, and no-smokers were individuals who
had never smoked. Accordingly, each risk factor was coded as
either present or absent. Written informed consent was
obtained from all study participants.
Genotyping
Screening for inherited prothrombotic conditions, including
the G1691A mutation in the factor V Leiden gene, the
G20210A mutation within the 30-untranslated region of the
PT gene, and the C677T MTHFR polymorphism, were
performed in all subjects by using a multiplex allele-specific
PCR assay (Nuclear Laser Medicine, srl), as previously
described12,22.
Statistical analysis
All statistical analyses were conducted using the Statview
statistical package, version 5.0.1 (SAS Institute, Abacus
Concepts, Inc., Berkeley, CA, USA). Data were expressed as
the mean+ standard deviation. Differences between the
means of the two continuous variables were evaluated by
Student’s t-test. Differences in non-continuous variables and
genotype distribution were tested by w2 analysis. Uncondi-
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tional logistic regression was used to calculate odds ratios
(ORs) and 95% confidence intervals (CIs). A p value of 0.05
was considered statistically significant.
RESULTS
Thrombosis-free cohort
Anamnestic data demonstrated a positive first-degree family
history of venous and/or arterial thrombotic events in 48
women (33.1%). No significant differences were observed for
traditional thrombotic risk factors between women with or
without family history (Table 1). The prevalence of pro-
thrombotic mutations, factor V Leiden and PT G20210A, was
higher in thrombosis-free women with a positive family
history compared with women without (10.4% vs. 1.0%;
w2¼ 7.1, p¼ 0.008 for factor V Leiden, and 6.2% vs. 1.0%;
w2¼ 3.3, p¼ 0.07 for PT G20210A, respectively). The
frequency of women carrying at least one prothrombotic
mutation (factor V Leiden or PT G20210A) was significantly
higher in the group with a positive family history than in the
group without (16.7% vs. 2.1%, w2¼ 10.7, p¼ 0.001). No
significant differences were observed for the MTHFR 677TT
genotype (29.2% vs. 25.8%; p¼ 0.7) (Table 1).
Cohort of women with personal history of
thrombosis
As expected, the women who had experienced previous
thrombotic events showed a higher prevalence of hypertension
(p5 0.0001), dyslipidemia (p50.0001), diabetes
(p¼ 0.0001), and family history (p50.0001) compared with
the thrombosis-free group (Table 2).
The frequency of either factor V Leiden or PT G20210A
prothrombotic mutation was also higher, although not
significant, in these patients when compared with the
thrombosis-free group (12.4% vs. 6.9%). No significant
alterations were observed with regard to other coagulation
defects, including protein C, protein S and antithrombin III.
Patients with a positive family history also had a higher
prevalence of prothrombotic mutations compared with those
without (15.7% vs. 7.8%, p¼ 0.2).
Moreover, we observed that the frequency of either factor V
Leiden or PT G20210A variant was significant higher in this
group of patients when compared to thrombosis-free women
without a family history (12.4% vs. 2.1%; w2¼ 7.9,
p¼ 0.005). On the contrary, no significant difference in the
proportion of prothrombotic defects was observed between
patients and thrombosis-free women with a positive family
history (12.4% vs. 16.7%; w2¼ 0.5, p¼ 0.5) (Figure 1). The
overall odds ratio for thrombotic events in the presence of one
prothrombotic mutation was 2.0 (95% CI 0.9–4.4, p¼ 0.09).
Multivariate regression analysis showed a synergic effect
between the presence of one prothrombotic mutation and
family history on the risk of thrombosis (OR 3.7, 95% CI 1.9–
7.2) (Table 3).
DISCUSSION
Our data showed a high sensitivity of a positive family history
of early thrombosis in identifying prothrombotic mutations in
asymptomatic women before starting HRT. In the last
decades, the potential cardioprotective effects of HRT have
been extensively investigated, with controversial results23.
Observational studies have suggested a significant reduction in
cardiovascular events after HRT, but large clinical trials have
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Table 1 Clinical and demographic characteristics of the thrombosis-
free cohort of women. Data are given as mean+ standard deviation
or n (%)
Positive
family
history
(n¼48)
Negative
family
history
(n¼ 97) p Value
Age (years) 52.0+ 4.9 50.7+5.6 0.2
Smoking habit 0.7
no smoking 31 (64.6) 65 (67.0)
past-smoking 7 (14.6) 10 (10.3)
smoking 10 (20.8) 22 (22.7)
Hypertension 5 (10.4) 18 (18.6) 0.2
Dyslipidemia 11 (22.9) 24 (24.7) 0.8
Diabetes mellitus 0 (0) 2 (2.1) 0.3
Body mass index (kg/m2) 24.7+ 4.3 26.0+5.3 0.2
Homocysteine (mmol/l) 11.1+ 7.2 11.0+6.0 0.9
677TT MTHFR genotype 14 (29.2) 25 (25.8) 0.7
Factor V Leiden variant 5 (10.4) 1 (1.0) 0.008
Prothrombin 20210A variant 3 (6.2) 1 (1.0) 0.07
Table 2 Demographic and genetic characteristics of the study
population according to the presence of thrombotic events. Data are
given as mean+ standard deviation or n (%)
Thrombosis-
free women
(n¼145)
Patients
(n¼121) p Value
Age (years) 51.2+5.4 54.0+9.1 0.002
Smoking habit 0.5
no smoking 96 (66.2) 80 (66.1)
past-smoking 17 (11.7) 19 (15.7)
smoking 32 (22.1) 22 (18.2)
Hypertension 23 (15.9) 51 (42.1) 50.0001
Dyslipidemia 35 (24.1) 68 (56.2) 50.0001
Diabetes mellitus 2 (1.4) 16 (13.2) 0.0001
Family history 48 (33.1) 73 (60.3) 50.0001
Body mass index (kg/m2) 25.6+5.0 26.1+5.5 0.5
677TT MTHFR genotype 39 (26.9) 26 (21.5) 0.3
Factor V Leiden variant 6 (4.1) 6 (5.0) 0.7
Prothrombin 20210A variant 4 (2.8) 9 (7.4) 0.08
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demonstrated that hormone therapy may increase cardiovas-
cular risk in late postmenopausal women3,7,24–29. The
apparent discrepancy between these results recently seems to
be explained in terms of time to initiation of therapy8–11,30.
Estrogen therapy used from the time of menopause onward
may be cardioprotective because of the responsiveness of the
endothelium to estrogen that buffers the detrimental effects on
coagulation. However, if HRT is instituted after endothelial
damage has occurred in late postmenopausal women, the
beneficial effects on the vessel wall are not observed because of
the predominance of the pro-coagulant or plaque-destabilizing
effects, leading to an increase in cardiovascular risk31,32. In
fact, in a recent statement by European cardiologists and
gynecologists10, Practice point 6 states that ‘Cardiovascular
risk associated with hormone therapy exceeds the benefit in
elderly post-menopausal women. In treating the younger,
perimenopausal woman for menopausal symptoms, the
benefits should be weighed against the potential risks of
hormone replacement therapy.’ In just this subset of women,
other concomitant factors may be involved, including the
presence of cardiovascular risk factors or individual suscept-
ibility. Recently, it has been suggested that the benefit of HRT
could be obscured by an increased risk of thrombotic events in
women genetically predisposed to thrombotic complica-
tions12. In particular, the presence of the factor V Leiden
and/or prothrombin gene mutation may increase the risk for
thrombosis in HRT users12,14–19. The Estrogen and Throm-
boembolism Risk (ESTHER) study confirmed the associations
between increased venous thromboembolism risk in post-
menopausal women and the presence of either factor V Leiden
or PT G20210A mutation13. Moreover, among postmeno-
pausal hypertensive women, the association between HRT use
and myocardial infarction risk is higher in the presence of the
prothrombin G20210A variant18. In such women, the safety
of hormone therapy is questionable and a genetic screening for
thrombotic risk factors might permit a better assessment of
the risks and benefits associated with HRT12. In the last
decade, genetic testing for the identification of individual
susceptibility has become common practice20. However, there
is considerable debate over the psychological and social
problems of genetic testing in asymptomatic individuals20.
The usefulness of genetic screening in women prior to
prescribing hormone therapy is not yet well defined. As a
consequence, indiscriminate thrombotic screening is deemed
not to be cost-effective. Our findings strongly support the
belief that a selective screening in women with a personal and/
or family history of venous and arterial thrombosis is strongly
recommended, in an attempt to increase cost-effectiveness and
avoid denial of the benefits of hormonal therapy to many
women. In the literature, there is no agreement on the value of
the family history for the selection of patients who should be
screened for thrombophilia. Some reports have demonstrated
a low sensitivity and positive predictive value of family history
of venous thromboembolism for identifying women with
thrombophilia, suggesting that a policy of selective screening
may therefore miss a substantial number of women at
increased risk of thrombotic complications when taking oral
contraceptives33,34. However, a recent meta-analysis showed
that selective screening based on previous personal and/or
family history of venous thromboembolism was more cost-
effective in all four different patient groups considered:
women prior to prescribing oral contraceptives or HRT,
women at the onset of pregnancy, and patients prior to major
orthopedic surgery, compared with no screening35.
An undoubted limitation of our study is the low number of
women, which may make the results of our interaction
analysis statistically unstable, although the present study is
sufficiently powered in the case of odds ratios43.
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Table 3 Risk factors for thrombotic events according to multiple
logistic regression analysis in the study population
Risk factors
Odds ratio (95%
confidence
interval) p value
Age (years) 1.0 (0.9–1.1) 0.7
Smoking habit 1.0 (0.6–1.6) 0.9
Hypertension 3.8 (1.5–9.7) 0.005
Dyslipidemia 4.4 (1.9–10.0) 0.0003
Diabetes mellitus 6.5 (0.8–54.8) 0.08
Body mass index 0.9 (0.9–1.0) 0.4
Family history 3.1 (1.9–5.1) 0.0001
Prothrombotic mutation 4.2 (0.9–19.3) 0.05
Family history þ prothrombotic
mutation
3.7 (1.9–7.2) 0.0001
Figure 1 Percentage of prothrombotic mutations according to family
and personal history of thrombosis
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In conclusion, hormone therapy should be discussed with
each patient, taking into account the prevalence and the
relevance of the patient’s symptoms and risk factors. Each
woman should be counselled regarding the risks and perceived
benefits of the therapy. Genetic screening provides a useful
tool for gynecologists in order to improve the safety and
efficacy of individualized HRT and might be advisable in
women with a family history of thrombotic events in order to
minimize adverse drug reactions in high-risk subjects.
Conflict of interests The authors declare no conflict of
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